Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Non-hormonal period Clear all
Not yet recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 4, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03194646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Standard of care
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 4, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prune Consumption and Bone Health in Young Women Using Hormonal Contraceptives

NCT04785131
View directory record Official record
Conditions
Osteoporosis Risk
Interventions
Prune
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

NCT03783546
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Usual Care
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 4, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional

Contraceptive Hormones and Women With Cystic Fibrosis

NCT02144246
View directory record Official record
Conditions
Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception
Interventions
Non-hormonal period, Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 4, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chronic Pain Risk Associated With Menstrual Period Pain

NCT02214550
View directory record Official record
Conditions
Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
Interventions
cyclic microgestin 1/20, continuous microgestin 1/20
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 4, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Myeloid to Adipocyte Transdifferentiation in Human Cells

NCT02654925
View directory record Official record
Conditions
Obesity
Interventions
Adipose Tissue Biopsy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 100 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 4, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Pain Control With Hormonal IUS Insertion

NCT02352714
View directory record Official record
Conditions
Pain
Interventions
Paracervical Nerve Block, Sham Paracervical Block
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 4, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

NCT02020070
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
Degarelix, Ipilimumab, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 4, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029
View directory record Official record
Conditions
Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions
Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream)
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 4, 2026, 4:40 PM EDT